A whole population-based cohort study of the trajectory of the prevalence and the incidence of mental illness, challenging behaviour, and psychotropic medication prescribing in adults with intellectual disabilities in the Czech Republic between 2010 and 2022

Deb S[1], Jarkovský J[2], Melicharová H[2], Holub D[3], Limbu B[1], Třešňák P[4].

[1]*Professor Shoumitro Deb, MBBS, FRCPsych, MD Visiting Professor of Neuropsychiatry, Department of Brain Sciences, Faculty of Medicine, Imperial College London, 2nd Floor Commonwealth Building, Du Cane Road, London W12 0NN, UK. Phone: 00442083834161, email address: s.deb@imperial.ac.uk https://orcid.org/0000-0002-1300-8103

*Corresponding author.

[2]Dr Jiří Jarkovský, RNDr. PhD, Head of the Institute of Health Information and Statistics of the Czech Republic & Institute of Biostatistics and Analyses, Faculty of Medicine, Masaryk University, Czech Republic, Netroufalky 5, 625 00, Brno, Czech Republic. Phone: +420 603954829, e-mail address: jiri.jarkovsky@uzis.cz https://orcid.org/0000-0002-1400-0111

[2]Ms Hana Melicharová, Senior Data Analyst, Institute of Health Information and Statistics of the Czech Republic, Netroufalky 5, 625 00, Brno, Czech Republic. Phone: +420 603954829, e-mail address: hana.melicharova@uzis.cz

[3]Dr David Holub, PhD, Consultant Psychiatrist, Institute for Medical Humanities, 1st Medical Faculty, Charles University Karlovo náměstí 40, 128 08 Praha 2, Czech Republic. Phone: +420732500403, email address: holub.mail@gmail.com https://orcid.org/0000-0002-3781-4679

[1]Miss Bharati Limbu, BSc, Research Assistant, Department of Brain Sciences, Faculty of Medicine, Imperial College London, 2nd Floor Commonwealth Building, Du Cane Road, London W12 0NN, UK. Phone: 00442083834161, email address: b.limbu@imperial.ac.uk https://orcid.org/0000-0002-3532-0640

[4]Petr Třešňák, MSc, Parent of an autistic child and the Chairman of the Children of the Full Moon, NGO, Bubenska 6, Prague 8, Czech Republic. Phone: +420 777 864 248, email address: petr.tresnak@detiuplnku.cz https://detiuplnku.cz/cs/home/

Abstract

Background

It is essential to understand using a sizeable, centralised health database, the complex relationship among mental illness, challenging behaviour and psychotropic medication prescribing to help reduce the inappropriate overmedication of adults with intellectual disabilities. Diagnosing mental illness in adults with intellectual disabilities could be difficult because of the communication challenges and sometimes atypical manifestation, for example, through challenging behaviour.

Method

We explored the change in prevalence between 2010 and 2022 and incidence of mental illness, challenging behaviour and psychotropic medication prescribing between 2015 and 2022 among adults with intellectual disabilities and the relationships among them using a national health register in the Czech Republic. We collected data from the Institute of Health Information and Statistics of the Czech Republic.

Results

62,636 (54% males) adults with intellectual disabilities contributed 704,503 person-years of data. In 2010, the prevalence of overall mental illness was 15·7%, challenging behaviour 29% and any psychotropic prescription 55%, increasing significantly by 2022 to 17·3%, 30·5% and 59%, respectively. The prevalence of overall mental illness, anxiety disorder, autism, ADHD and challenging behaviour increased significantly between 2010 and 2022. On the other hand, the incidence of newly diagnosed cases of most mental illnesses and challenging behaviour decreased significantly between 2015 and 2022. In contrast, the incidence of autism, ADHD, sleep disorders, and dementia increased significantly between 2015 and 2022. The incidence of challenging behaviour correlated significantly with psychoses, bipolar, anxiety and personality disorders. The prevalence of most psychotropic prescriptions increased significantly from 35% for antipsychotics, 17% for antidepressants, and 23% for mood stabilisers in 2010 to 37% for antipsychotics, 25% for antidepressants, and 28% for mood stabilisers in 2022 apart from anxiolytics which decreased from 14% in 2010 to 13% in 2022, despite a drop in the incidence of new prescriptions. The rate of psychotropic prescribing correlated significantly with the rate of mental illness and challenging behaviour. Among those receiving antipsychotics, only 18% in 2010 and 19% in 2022 had severe mental illness for which antipsychotics are indicated. Therefore, in >80% of cases, antipsychotic medications were prescribed off-label primarily for challenging behaviour. Similar trends were observed for other psychotropics. For example, mood stabilisers and antidepressants were prescribed more often for challenging behaviour in 38%-40% and 33%-40% of cases, respectively, than bipolar disorder (1%) and depression (8%-11%), respectively. In 2010, among those with challenging behaviour, 82% were prescribed any psychotropic medications, 62% antipsychotics, 20% antidepressants, and 30% mood stabilisers, increasing significantly by 2022 to 87%, 63%, 33%, and 37%, respectively. However, the prevalence of anxiolytic prescribing decreased significantly from 17% in 2010 to 14% in 2022. The incidence rates of new prescriptions for challenging behaviour fell by 1·1% for any

psychotropic medications, 0·8% for antipsychotics, 0·7% for antidepressants and 0·1% for anxiolytics, but increased by 0·3% for hypnotics/sedatives and 0·4% for mood stabilisers.

Conclusions

The prevalence of mental illness and challenging behaviour increased over 12 years despite a drop in their incidences. This may indicate the chronic nature of these conditions. Challenging behaviour was significantly associated with some mental illnesses. Both mental illness and challenging behaviour were significantly associated with psychotropic medication prescribing. The prevalence of all psychotropic medication prescribing overall and especially for challenging behaviour was high and increased significantly over 12 years. This probably indicates long-term use of these medications. Antipsychotic medications were prescribed for severe mental illness only in a minority of cases. This indicates an off-licence use of antipsychotic medications in a very high proportion of cases. This trend of off-licence use was also evident in other psychotropic medications than antipsychotics. On the contrary, these medications were primarily used for challenging behaviour. The incidence of new prescriptions of antipsychotics, antidepressants, and anxiolytics decreased over the years, possibly at the expense of increased new prescriptions of mood stabilisers, primarily antiepileptics and also hypnotics/sedatives. The reasons for the significant increase in already high psychotropic medication prescription over 12 years and the trend of increase in new prescriptions of mood stabilisers and hypnotics/sedatives require scrutiny.

Keywords: Adults with intellectual disabilities, mental illness, challenging behaviour, psychotropic medications, prevalence, incidence, cohort study, Czech Republic.

Introduction

About 0·5-0·7% of the general adult population have intellectual (learning) disabilities (Carey et al., 2016; NHS Digital, 2021; Maulik et al., 2022). Intellectual disabilities are a group of etiologically diverse conditions originating during the developmental period, characterised by significantly below-average intellectual functioning and adaptive behaviour (WHO, 2004). Like the general population, adults with intellectual disabilities are prone to a whole range of mental illnesses. However, diagnosing mental illness in adults with intellectual disabilities could be difficult because of the communication challenges and sometimes atypical manifestation, for example, through challenging behaviour (Deb et al., 2022a; Deb et al., 2022b). It is, therefore, essential to understand the relationship between mental illness and challenging behaviour in this population using a sizeable, centralised health database. Otherwise, there is a danger of inappropriate overuse of psychotropic prescriptions for challenging behaviour. The overmedication of adults with intellectual disabilities is a significant public health concern (de Kuijper et al., 2010; Sheehan et al., 2015; Mehta & Glover, 2019; Song et al., 2023) as the RCT-based evidence for the efficacy of psychotropics for challenging behaviour in the absence of a mental illness among adults with intellectual disabilities is weak (see Deb, 2024 for a review), but the evidence of harm caused by the medication's adverse effects is substantial (Ramerman et al., 2018; Deb et al., 2023; Sun et al., 2023)). The World Psychiatric Association (WPA) (Deb et al., 2009) and the UK NICE (NICE, 2015) have developed guidelines to address this issue along with the NHS England initiative STOMP (STopping Over-Medication of People with ID, autism

or both) (Branford et al., 2018). All these guidelines recommend the use of non-pharmacological interventions such as positive behaviour support (PBS) (Gore et al., 2022) first before prescribing psychotropic medications for challenging behaviour. However, there has not been a longitudinal study to assess the impact of these guidelines on psychotropic prescribing for mental illness and challenging behaviour.

Therefore, we studied the change in the prevalence and incidence of mental illness, challenging behaviour, and psychotropic medication prescribing using the International Classification of Diseases-10th revision (ICD-10) (WHO, 2004) in adults with intellectual disabilities between 2010 and 2022 in the Czech Republic to assess the impact of NICE and WPA guidelines and the UK STOMP initiative on psychotropic medication prescribing in this population and its relationship with mental illness and challenging behaviour.

Method

We collected data from the National Registry of Reimbursed Health Services (NRRHS) in the Czech Republic. NRRHS contains all healthcare data provided under public health insurance, which covers almost 100% of the population in the Czech Republic. NRRHS is part of the National Health Information System (NHIS) regulated by the Institute of Health Information and Statistics of the Czech Republic (“IHIS CR“ or “the Institute“). The Ministry of Health in the Czech Republic established the Institute in 1960 to implement the Health Services Act. The Institute follows the principles of the European Statistics Code of Practice, which represents a common summary of European standards designated for statistical organisations and the whole European statistical system to secure a high quality and credibility of European data. In the Czech Republic, all adults are registered with this national registry to receive reimbursement for their health service costs. The health data such as the diagnosis, treatment and diagnostic tests on all adults in the country who have come across any health service such as in-patient, outpatient or community provided by any specialities such as medicine, surgery, psychiatry, including health professionals like doctors including general practitioners and nurses and other allied health professionals like physiotherapists, psychologists, occupational therapists, radiologists, haematologists, etc. The International Classification of Diseases-10th revision (ICD-10) (WHO, 2004) criteria are used by all who input data into the national register. The prevalence data were collected from 2010, the year after the WPA international guideline (Deb et al., 2009) was published, until 2022, the last year ICD-10 diagnoses were made, as ICD-11 (WHO, 2019) was published in 2022. The incidence rates of the first occurrence of episodes within the last five years were collected from 2015 to 2022, allowing for the recording of only new entries that were not present prior to 2015.

We have identified adults with intellectual disabilities using the ICD-10 codes of F70-79 from any service, either as a primary or a secondary diagnosis. The intellectual disabilities diagnosis was subdivided into F70 mild intellectual disabilities, F71 moderate intellectual disabilities, F72 severe intellectual disabilities, F73 profound intellectual disabilities, F78 other intellectual disabilities, and F79 unspecified intellectual disabilities. The diagnosis of challenging behaviour was made using the ICD-10 codes F70x.1 (significant impairment of behaviour requiring attention or treatment) and F70x.8 (other impairments of behaviour). A psychiatric diagnosis is recorded using the following ICD-10 codes. F20-29: schizophrenia, schizotypal and delusional

disorders (psychoses); F30-31: bipolar disorder; F32-39: depressive disorder; F40-48: anxiety disorders; F51: sleep disorders; F60-69: personality disorders; and F00-03: dementia. We used F84 for autism spectrum disorder and F90 for ADHD diagnosis. To compare our findings with the previous English general practice register-based study (Sheehan et al., 2015), we recorded a diagnosis of a severe mental illness if someone had a diagnosis of F20-29 (psychosis) and/or F30-31 (bipolar disorder) and also a diagnosis of any psychiatric disorder if someone has any of the following ICD-10 diagnosis; F20-48 (psychoses, bipolar disorder, depressive disorder and anxiety disorders).

We have utilised the WHO Anatomical Therapeutic Chemical (ATC) codes and the Therapeutic Chemical Classification systems (www.whocc.no/atc-do-index, accessed on 25.03.2025) to classify psychotropic medication groups. The following codes were used. N05A: antipsychotics; NO6A: antidepressants; NO5B: anxiolytics (anti-anxiety medications); NO5C: hypnotics/sedatives; NO3: Anti-epileptic medication; NO5AN: lithium. Anyone receiving NO5AN, NO3AX, NO3AF or NO3AG is recorded as receiving a mood stabiliser. Anyone receiving any of these medications was recorded as receiving any psychotropic.

Statistical analysis

The data were processed using the Vertica 9 database and analysed using SPSS 29.0.1.0 (IBM Corporation 2023) and STATA/IC 15.1.

Absolute and relative frequencies were used as standard descriptive statistics for categorical data. The incidence rate ratio (IRR) and its statistical significance were adopted to compare the occurrence of psychotropic prescriptions between years. Binary logistic regression analyses were used to determine factors influencing the occurrence of psychotropic medication, mental illness, and challenging behaviour among adults with intellectual disabilities. We estimated models using the stepwise forward conditional method. If adults with intellectual disabilities received a new prescription of psychotropic medication or a diagnosis of a mental illness or challenging behaviour after cohort entry (that is, during follow-up), we considered them no longer at risk for that psychotropic prescription or mental illness or challenging behaviour and removed them from the cohort.

We conducted multivariate regression analysis using the incidences of mental illnesses as dependent variables and age, gender, severity of intellectual disabilities, and incidence of challenging behaviour as the independent variables. We also conducted multivariate regression analysis using the incidences of new prescriptions of different psychotropic medications as dependent variables and gender, age, severity of intellectual disabilities, and incidences of challenging behaviour and different mental illnesses as the independent variables. We used Wald tests to assess the overall significance of categorical variables and categorical interaction terms. We considered a p-value of 0.05 to be statistically significant (two-tailed).

Patient and public involvement

Children of the Full Moon, a non-governmental parent organisation for people with autism spectrum disorder and intellectual disabilities in the Czech Republic, has been involved at every

stage of the study, from conceptualisation through design, data analysis, and paper writing. The organisation's chairman (PT), also the parent of a child with autism, is a co-author.

Results

Table 1 shows the prevalence (2010 and 2022) and the incidence rates of new cases (2015 and 2022) of different mental illnesses, challenging behaviours and neurodevelopmental disorders like autism and ADHD. In 2010, 53,551 adults had a diagnosis of intellectual disabilities. This figure increased to 58,678 in 2015 and 62,636 in 2022. The incidence rate is presented per 10,000 person-years to compare data with the previous English study (Sheehan et al., 2015). Figure 1 illustrates the trajectory of new cases recorded for various mental illnesses and challenging behaviours from 2015 to 2022, showing a decline in the incidence of new cases over the years, except for a slight increase in new cases of any mental illness and anxiety disorder between 2021 and 2022.

[Figure 1 here]

In 2010, the prevalence of overall mental illness was 15·7%, challenging behaviour 29% and any psychotropic prescription 55%, increasing significantly by 2022 to 17·3%, 30·5% and 59%, respectively. The prevalence of any mental illness and all individual mental illnesses, along with the neurodevelopmental disorders and challenging behaviour, increased between 2010 and 2022. The prevalence of any mental illness was 15.7%, anxiety disorder 7.4%, autism 0.7%, ADHD 0.5%, and challenging behaviour 29% in 2010, which increased significantly in 2022 to 17.3%, 9%, 3%, 2%, and 30.5%, respectively. On the other hand, the incidence of newly diagnosed cases of most mental illnesses and challenging behaviour decreased significantly between 2015 and 2022, apart from autism, ADHD, sleep disorder, and dementia, which increased significantly between 2015 and 2022.

[Table 1 here]

Table 2 shows the prevalence (2010 and 2022) and incidence (2015 and 2022) data on the overall prescription of psychotropic medications and the rate of psychotropic medications prescribed for challenging behaviour. We also presented prevalence data (2010 and 2022) on the proportion of those who received different psychotropic medications with different mental illnesses or challenging behaviours.

The prevalence of psychotropic medication prescribing among adults with intellectual disabilities increased significantly from 55% in 2010 to 59% in 2022. Similarly, antipsychotic prescribing increased significantly from 35% in 2010 to 37% in 2022, and antidepressants from 17% in 2010 to 25% in 2022. The prevalence of mood stabiliser prescriptions increased significantly from 23% in 20210 to 28% in 2022, and hypnotics/sedatives from 0.5% in 2010 to 1% in 2022. In contrast, the prevalence of anxiolytic prescribing fell significantly from 14% in 2010 to 13% in 2022.

Among those who showed challenging behaviour, a high proportion received psychotropic medications (82%) in 2010, significantly increasing in 2022 to 87%. A high proportion also

received antipsychotic medications (62%) in 2010, which increased significantly in 2022 to 63%. Similarly, the prevalence of antidepressant prescriptions for challenging behaviour increased significantly from 20% in 2010 to 33% in 2022, and mood stabilisers from 30% in 2010 to 37% in 2022. In contrast, the prevalence of anxiolytic prescriptions for challenging behaviour decreased significantly from 17% in 2010 to 14% in 2022.
[Table 2 here]

The incidence rates of new cases of psychotropic prescriptions are presented in Table 2 and Figure 2. The incidence rates decreased from 2015 to 2022 for most psychotropic medication prescriptions, apart from hypnotics/sedatives, which increased between 2015 and 2022. The trajectory showed a rise in incidence in most psychotropics in 2016, followed by a subsequent decrease in 2017. However, there was another rise in the incidence rates of most psychotropic medications in 2022 (the last year of data collection) (see Figure 2).

[Figure 2 here]

Whereas the incidence rate of new prescriptions of antipsychotics, antidepressants and anxiolytics decreased between 2015 and 2022 for those who displayed challenging behaviour, the rate of new prescriptions of hypnotics/sedatives and mood stabilisers increased significantly over the same period (see Table 2). Figure 3 shows that the incidence rates of new prescriptions for psychotropic medications to address challenging behaviour decreased during 2017-2018 and again in 2020-2021, with corresponding increases in 2019-2020 and 2022.

[Figure 3 here]

Among those who received antipsychotics, only 18% in 2010 and 19% in 2022 had a diagnosis of severe mental illness for which they are indicated (see Table 2). This means that in over 80% of cases, antipsychotics were prescribed when there was no severe mental illness present. On the contrary, among those who received antipsychotics, 51% in 2010 and 52% in 2022 had a diagnosis of challenging behaviour. Antidepressants were prescribed for depressive disorders only for 11% in 2010 and 8% of cases in 2022. On the other hand, antidepressants were prescribed in 33% of cases in 2010 and 40% in 2022 for challenging behaviour. Similarly, anxiolytics were used for anxiety disorders only for 16% in 2010 and 19% of cases in 2022 but for challenging behaviour in 35% of cases in 2010 and 33% in 2022. Similarly, mood stabilisers were prescribed for challenging behaviour in 38% of cases in 2010 and 40% in 2022. In contrast, mood stabilisers were prescribed for only 1% of cases of bipolar disorder in 2010 and 2022 (see Table 2).

Table 3 shows the demographic characteristics of all adults with a diagnosis of intellectual disabilities in 2022 (n=62,636), new cases of adults with intellectual disabilities who showed challenging behaviour (n=2147), and those receiving new prescriptions of any psychotropic medications in 2022 (n=2398). Demographic distribution showed a higher rate of males, a lower age group (<40 years) and mild intellectual disabilities among those who have intellectual disabilities, but also those who showed challenging behaviour and received any psychotropic medications.

[Table 3 here]

Table 4 shows the results of multivariate regression analysis. The incidence of challenging behaviour correlated significantly with the incidences of psychoses, bipolar, anxiety and personality disorders.

The female gender was significantly associated with the incidences of bipolar disorder (<0.005), depressive disorder ($p<0.001$), anxiety disorder ($p<0.001$), and personality disorder ($p<0.001$). Older age was significantly related to the incidences of psychoses ($p<0.05$), depressive disorder ($p<0.001$), anxiety disorder ($p<0.001$) and personality disorder ($p<0.001$). Severe and profound intellectual disabilities were significantly associated with the incidences of psychoses ($p<0.001$), anxiety disorder ($p<0.005$) and personality disorder ($p<0.001$).

[Table 4 here]

Table 5 presents the findings from a multivariate regression analysis, using the incidence of new psychotropic prescribing as the dependent variable. The rate of challenging behaviour was significantly associated with the rate of prescription of any psychotropic medication ($p<0.001$), antipsychotics ($p<0.001$), antidepressants ($p<0.001$), and anxiolytics ($p<0.001$). The female gender was statistically significantly associated with the prescription of antidepressants and anxiolytics but not antipsychotics and mood stabilisers. Older age (>65 years) was statistically significantly related to the prescription of all psychotropic medications. The more severe intellectual disabilities (severe and profound intellectual disabilities) were statistically significantly associated with the prescription of all psychotropics apart from antipsychotic medication. Anxiety disorder was statistically significantly associated with all psychotropic medication prescriptions.

[Table 5 here]

Discussion

Mental illness, neurodevelopmental disorders and challenging behaviour

Although the overall prevalence of mental illness increased significantly over the 12-year study period between 2010 (15·7%) and 2022 (17·3%), the prevalence of most individual mental illnesses remained similar, apart from anxiety disorder, which increased significantly from 7·4% to 9%. However, the prevalence of challenging behaviour, autism and ADHD have all also increased significantly over the 12 years. The prevalence of mental illnesses, neurodevelopmental disorders, and challenging behaviour among adults with intellectual disabilities varied widely in previous studies for obvious methodological reasons (Deb et al., 2022a). Ours is the first large national health register-based study that used ICD diagnosis, which had not been done previously for adults with intellectual disabilities using a large national health database. However, the overall prevalence of mental illness and challenging behaviour found in the current study is similar to what was reported in some previous studies (Deb et al., 2022a). For example, a whole population-based cohort study of adults with intellectual disabilities in Scotland found the overall prevalence (Henderson et al., 2020) of mental illness and severe

mental illness among 16.3% and 6.2% of the cohort (n=1190), respectively, at study entry in 2002-2004 compared with 15.7% and 7.4% respectively in the current study at study entry in 2010 (n=53,551). Similarly, in the Scottish study, depressive disorder was diagnosed among 4.3%, anxiety disorder in 2.7%, autism in 7.6%, and ADHD in 1.3% of the cohort, compared with 3%, 9%, 3%, and 2%, respectively in the current study in 2022. The significant rise in the prevalence of anxiety disorders in the current study over the 12 years may be a reflection of clinicians' better awareness over the last decade of the presence of anxiety disorders in adults with intellectual disabilities. Similarly, the significant rise in the prevalence of autism and ADHD during the same period is likely to be due to a better awareness of these diagnostic categories among clinicians.

The reported prevalence of challenging behaviour varied widely in previous studies because of the different methodologies used. A significant problem has been defining and diagnosing challenging behaviour in this population. The current study employed an ICD-10 diagnosis, which has not been used in previous studies, to diagnose challenging behavior, despite the fact that ICD-10 provides an explicit qualifier with an extended ‘x’ code for this diagnosis. Despite these methodological differences, the prevalence of challenging behaviour reported in the current study is similar to some earlier studies (Deb et al., 2022a, b). For example, in the Scottish population-based study (Henderson et al., 2020), 20.5% of the cohort at study entry exhibited challenging behavior, compared with 29% in the current study at study entry. The significant rise in the prevalence of challenging behaviour from 2010 to 2022 in the current study is difficult to explain. It may be the effect of the Covid-19 pandemic, which has shown increased challenging behaviour in most recent studies (Gil-Llario et al., 2023). There may be even greater awareness among clinicians of this diagnosis, or they may have used the ICD-10 codes more frequently for this diagnosis in 2022 than in 2010. However, the incidence rate of new challenging behaviour cases fell by 0·6% from 404 per 10,000 person-years in 2015 to 343 in 2022. An increased prevalence rate of challenging behaviour over the years, despite the decrease in the incidence rate, may be due to the chronic nature of challenging behaviour. The incidence rates of most conditions fell significantly apart from sleep disorders, autism and ADHD, all of which increased over seven years, and the increase in autism and ADHD rates was statistically significant.

Psychotropic medication prescribing

The prevalence of psychotropic medication prescribing among adults with intellectual disabilities between 2010 and 2022

The reported prevalence rates of psychotropic medication prescribing for adults with intellectual disabilities in previous studies varied from as low as 10% to as high as 67%, depending on the method of data collection (Song et al., 2023; Deb, 2024). In a recent meta-analysis of 24 studies, Song and colleagues (Song et al., 2023) reported a pooled prevalence of psychotropic prescribing in adults with intellectual disabilities. Pooled prevalence for any psychotropic prescription was 41% (95% confidence interval (CI) 35-46%), antipsychotics 31% (95% CI 27-35%), antidepressants 14% (95% CI 9-19%), anxiolytics 9% (95% CI 4-15%), and hypnotics/sedatives 5% (95% CI 2-8%) (Song et al., 2023). This shows that apart from the prevalence of overall psychotropic medications and hypnotics/sedatives prescription among adults with intellectual disabilities in the current study, the prevalence rates of other psychotropic medication

prescriptions at the study entry were within the 95% confidence intervals reported in the recent meta-analysis (Song et al., 2023). In the English general practice register-based study of 33,016 adults with intellectual disabilities (Sheehan et al., 2015), the rate of any psychotropic prescription was 49% at study entry in 1999 and 63% at the study end in 2013. This compares with the 55% prevalence of any psychotropic prescription in 2010 and 59% in 2022 in the current study. The rate of increase in psychotropic medication prevalence in our study over 12 years was lower than in the English study over 15 years. The most commonly prescribed psychotropic medication was antipsychotics in 2022 (37%), followed by mood stabilisers, primarily antiepileptics (28%), antidepressants (25%), anxiolytics (13%) and hypnotics/sedatives (1%). This compares with a recent study among adults with intellectual disabilities in community homes and supported living accommodations in England and Wales in the UK which reported of 190 prescriptions 47% were antipsychotics followed by 23% antidepressants, 13% antiepileptics, 7% anxiolytics in the form of benzodiazepine (Deb et al., 2025).

The prevalence of antipsychotic medication prescription among adults with intellectual disabilities in the current study was much higher than in the general population, which is less than 1% (Marston et al., 2014). Whereas 35-37% of the adults with intellectual disabilities were prescribed antipsychotics in the current study, only 7.4-7.8% had a diagnosis of psychosis and/or bipolar disorder (severe mental illness) for which antipsychotics are licensed. This shows that in the vast majority of cases, antipsychotics were not prescribed for severe mental illness. The prevalence of antidepressant prescribing in the current study was much higher than the general population, which is 10.3% (NHS Digital, 2021). Whereas 17-25% of the adults with intellectual disabilities were prescribed antidepressants, only 3% had a diagnosis of depressive disorder in the current study for which antidepressants are licensed. This shows that in the vast majority of cases, antidepressants were not prescribed for depressive disorder.

The incidence of new psychotropic prescriptions among adults with intellectual disabilities between 2015 and 2022

The incidence of new prescriptions of any psychotropic medications was 503 in 1999 and 533 per 10,000 person-years in 2013 in the English study (Sheehan et al., 2015), compared with the incidence rate of new psychotropic medications prescriptions of 457 in 2015 and 383 per 10,000 person-years in 2022 in the current study, which was lower than the rates in the English study at both data entry points. Whereas the English study (Sheehan et al., 2015) showed an increase in the incidence rate of new prescriptions for most psychotropic medications over 15 years, the current study showed a decrease in the incidence rate of most psychotropic medication prescriptions over seven years, except for an increase in hypnotic/sedative prescriptions. Despite this decrease in the incidence rate in the current study, apart from a reduction in anxiolytic prescriptions, the prevalence of antipsychotics, antidepressants, hypnotics/sedatives, and mood stabilisers increased significantly between 2010 and 2022. This is likely due to the long-term use of these medications. The reasons for this require urgent scrutiny to prevent inappropriate long-term prescribing of psychotropic medications in adults with intellectual disabilities.

However, Figure 2 shows a rise in incidences in almost all psychotropic medications around 2016, followed by a subsequent fall in 2017, and another rise in 2022, which is the last year of data collection in the current study. This increase is difficult to explain and may not directly

relate to the COVID-19 effect (Gil-Llario et al., 2023). A similar trend was reported in the English study (Sheehan et al., 2015), in that after a reduction in 2010-11 in the incidence of new prescriptions of anxiolytics and antidepressants, there was a subsequent increase in 2012-13. However, it is difficult to understand why the incidence of new anxiolytic prescriptions decreased in the current study between 2015 and 2022 when the prevalence of anxiety disorder diagnosis significantly increased over the same period. One possible explanation is that more clinicians may be using SSRIs instead of anxiolytics to treat anxiety disorders in recent years.

The prevalence of psychotropic medication prescribing between 2010 and 2022 among adults with intellectual disabilities who showed challenging behaviour

The prevalence of antipsychotic prescriptions among those who showed challenging behaviour in the current study was higher than that reported in the English study (Sheehan et al., 2015). For example, 47% of those with challenging behaviour received antipsychotics in the English study (Sheehan et al., 2015) compared with 62% in 2010 and 63% in 2022 in the current study. One possible explanation is that there is a relative lack of availability of non-pharmacological interventions for challenging behaviour in the Czech Republic compared to the UK.

In previous studies, among those who received psychotropic medications, most received them outside their licensed indications (Holden and Gitlesen, 2004; de Kuijper et al., 2010; Sheehan et al., 2015; Deb, 2024; Deb et al., 2025). For example, in the current study, antipsychotics were prescribed for severe mental illness only in 18% of cases in 2010 and 19% in 2022, compared with 24% in the Norwegian (Holden and Gitlesen, 2004), 22% in the Dutch (de Kuijper et al., 2010), and 29% in the English study (Sheehan et al., 2015). A similar trend has recently been reported among adults with intellectual disabilities in community settings in England and Wales, where antipsychotics were prescribed for severe mental illness only in 19% of cases (Deb et al., 2025). This means in over 80% of cases when antipsychotics were prescribed off-label for adults with intellectual disabilities, there was no record of any severe mental illness for which antipsychotics are indicated. However, among those who received antipsychotic medications, the proportion for whom they were used for challenging behaviour in the current study was lower (51-52%) than the Dutch study (58%) (de Kuijper et al., 2010) and the English study (61%) (Sheehan et al., 2015). Like the previous studies (Holden and Gitlesen, 2004; de Kuijper et al., 2010; Sheehan et al., 2015), the current study clearly showed that antipsychotic medications were prescribed primarily off-license for challenging behaviour in adults with intellectual disabilities rather than mental illnesses for which they are licensed.

A similar trend was observed for other psychotropic medications in the current study. For example, antidepressants were prescribed for depressive disorder only in 8-11% of cases but were prescribed more often for challenging behaviour (33-40% of cases). Similarly, mood stabilisers were prescribed for bipolar disorder only in 1% of cases, whereas they were prescribed for challenging behaviour in 38-40% of cases (see Table 2). This compares with a recent community-based study of adults with intellectual disabilities, which showed antiepileptic medications were used for epilepsy less often (in 32% of cases) than challenging behaviour (in 40% of cases) (Deb et al., 2025). This shows that psychotropic medications are prescribed off-licence in a high proportion of cases, particularly for challenging behaviour in adults with intellectual disabilities against the NICE and the WPA guidelines recommendations (Deb et al.,

2009; NICE, 2015; Deb, 2024). However, the off-licence use of a licenced medication is not necessarily inappropriate if appropriate safeguards are implemented (Aitchison et al., 2013).

The incidence of new psychotropic medication prescriptions among adults with intellectual disabilities between 2015 and 2022 who showed challenging behaviours

However, the incidence of new prescriptions for challenging behaviour showed, despite a decrease in overall psychotropic prescribing along with antipsychotics, antidepressants, and anxiolytics, an increase in the hypnotics/sedatives and mood stabiliser prescriptions between 2015 and 2022. This shows that in the current study, the welcome decrease in new prescriptions for antipsychotics, antidepressants, and anxiolytics for treating challenging behaviour may have been achieved at the expense of a not so welcome rise in other psychotropic prescriptions, hypnotics/sedatives and mood stabilisers. An English paper from the UK reported a recent trend in increased antidepressant prescribing to compensate for the reduction in antipsychotic prescribing (Branford & Shankar, 2022).

Relationship among mental illnesses, challenging behaviour and psychotropic prescribing

The findings of a significant association among challenging behaviour and psychoses, bipolar, anxiety and personality disorders (see Table 4) are similar to what has been reported previously (Deb et al., 2022a, b). The incidences of psychoses, anxiety and personality disorders showed a significant association with more severe intellectual disabilities. However, diagnosis of mental illnesses, particularly schizophrenia, is unreliable in adults with severe and profound intellectual disabilities (see Deb et al., 2022a for a review). Similarly, challenging behaviour may have been diagnosed as anxiety and personality disorders in some cases, particularly among those with mild to moderate intellectual disabilities (Deb et al., 2022a, b).

The relationship between psychotropic medication prescribing and other variables

Table 5 showed that the incidences of psychotropic medication prescriptions were significantly higher in the presence of mental illness, challenging behaviour, older age and more severe intellectual disabilities. A higher incidence of psychotropic prescribing in those with a mental illness and challenging behaviour had been reported before (de Kuijper et al., 2010; Sheehan et al., 2015; Deb, 2024). The significant association in the incidence of psychotropic medication prescribing and adults with severe intellectual disabilities and older age could have been a confounding effect of a similar association of age and severity of intellectual disabilities with mental illnesses and challenging behaviour. The fact that the female gender in the current study was statistically significantly associated with the prescription of antidepressants and anxiolytics but not antipsychotics and mood stabilisers is difficult to explain. It is possible that clinicians consider anxiety and depression as underlying causes of challenging behaviour, more so among women with intellectual disabilities than men. A statistically significant association between older adults with intellectual disabilities and psychotropic medication prescribing is in keeping with previous studies among older adults with intellectual disabilities (Odalović et al., 2024).

Strengths and limitations

This is the first-ever population-based cohort study using a large national health database and ICD-10 of incidence and prevalence of mental illness, challenging behaviour and psychotropic medication prescribing and their relationship in adults with intellectual disabilities. No other large national health records-based study has used ICD criteria to diagnose mental illness and challenging behaviour before. Only one similar study in England used Reed codes from a general practice database to diagnose mental illness and challenging behaviour, which did not correspond with ICD-10 codes. They also used the British National Formulary rather than the WHO ATC for psychotropic medication classification used in this study. Therefore, it is difficult to generalise their findings outside England. No other large-scale study exists outside England, particularly in Eastern Europe. This is also the first study to assess the impact of WPA international, NICE guidelines, and the STOMP initiative in England, UK, on psychotropic medication prescribing for adults with intellectual disabilities.

Capturing data from the whole adult population with intellectual disabilities will never be possible as many adults with mild intellectual disabilities are not known to the services or do not receive the diagnosis of intellectual disabilities. In the current study, we aimed to be as inclusive as possible by capturing both primary and secondary diagnoses from psychiatric, medical, surgical, and other inpatient and outpatient settings, as well as laboratory and allied professional data. The total Czech adult population (18 years and older) was 8,688,840 in 2022 (data gathered from the Institute of Health Information and Statistics of the Czech Republic, provided by authors JJ and HM), and we captured data on 62,636 adults with intellectual disabilities. This gives a prevalence of 0·7% of intellectual disabilities in the Czech adult population. The prevalence of adults with intellectual disabilities is reported to be between 0·5% and 0·7% of the whole adult general population (Wittchen et al, 2011; Carey et al., 2016; Maulik et al., 2022; NHS Digital, 2021). The demographics of the intellectual disabilities' population in 2022 in the current study showed a higher proportion (54%) of males, younger age, and mild to moderate intellectual disabilities, all of which are in keeping with what would be expected from an intellectual disabilities' population-based sample (Carey et al., 2016; Maulik et al., 2022). Considering all these factors, we believe our sample is as representative of the total adult Czech population with intellectual disabilities as possible.

Conclusion

Despite the reduction in incidences of mental illness and challenging behaviour, the significant rise in their prevalence over 12 years may indicate the chronic nature of these conditions. The rate of challenging behaviour significantly correlated with mental illnesses. The rate of psychotropic medication prescribing was significantly correlated with the rate of mental illness and challenging behaviour. There is a high prevalence of psychotropic medication use among adults with intellectual disabilities in the Czech Republic. The prevalence of most psychotropic medication prescriptions increased statistically significantly between 2010 and 2022, despite a decrease in the incidence rates of new prescriptions of most psychotropic medications, apart from hypnotics/sedatives, which increased between 2015 and 2022. Most psychotropic medications were prescribed only in a minority of cases for mental illnesses for which they are licensed. In a high proportion of cases, psychotropic medications were prescribed off-licence for challenging behaviour. Despite a reduction in new prescriptions of antipsychotics, antidepressants, and anxiolytics between 2015 and 2022 for adults with intellectual disabilities

who showed challenging behaviour, which may be an impact of WPA and NICE guidelines, there was an increased rate of new prescriptions for hypnotics/sedatives and mood stabilisers. It, therefore, appears that the decrease in new prescriptions of antipsychotics, antidepressants, and anxiolytics may have been achieved at the expense of increased new prescriptions of hypnotics/sedatives and mood stabilisers. This is a worrying trend which requires further investigation. Similarly, the reasons for the significant rise in the prevalence rates of most psychotropic medications between 2010 and 2022, which goes against WPA and NICE guidelines, require stringent scrutiny to prevent future inappropriate overmedication of adults with intellectual disabilities, which is a significant public health concern.

Contributors:

Concept and design: Deb, Třešňák, Holub; Data acquisition, analysis, or interpretation of data: Jarkovský, Melicharová, Limbu, Deb; Drafting of the manuscript: Deb; Critical review of the manuscript: Deb, Jarkovský, Melicharová, Holub, Limbu, Třešňák. All authors approved the final version of the submitted manuscript.

Funding

This study was not supported by any external funding.

Ethical approval

Data in the National Health Information System (NHIS) are collected in compliance with Act No. 372/2011 Coll., on Health Services and Conditions of Their Provision. Due to this legal mandate, the retrospective analyses of data in our study did not require either an ethics committee approval or participants' informed consent.

References

1. Aitchison KJ, Baldwin DS, Barnes T. (2017) Use of licensed medicines for unlicensed applications in psychiatric practice. College Report (CR 210). *The Royal College of Psychiatrists*, London, UK.
2. Branford D, Gerrard D, Saleem N, Shaw C, Webster A. (2018) Stopping over-medication of people with intellectual disability, autism or both (STOMP) in England Part 1–history and background of STOMP. *Advances in Mental Health and Intellect Disabilities*, **13**: 31-40.
3. Branford D, Shankar R. (2022) Antidepressant prescribing for adult people with an intellectual disability living in England. *British Journal of Psychiatry*, **221**: 488-493. https://doi.org/10.1192/bjp.2022.34
4. Carey IM, Hosking FJ, DeWilde S. (2016) Learning disability registers in primary care. *British Journal of General Practice*, **351**.
5. de Kuijper G, Hoekstra P, Visser F, Scholte FA, Penning C, Evenhuis H. (2010) Use of antipsychotic drugs in individuals with ID in the Netherlands: prevalence and reasons for prescription. *Journal of Intellectual Disability Research*, **54**: 659-667.

6. Deb S. (2024) Psychopharmacology. In ‘Handbook of psychopathology in intellectual disability: Autism and Child Psychopathology series’ (ed. J Matson). *Springer International*. p. 395-416. https://doi.org/10.1007/978-3-031-66902-6_18
7. Deb S, Kwok H, Bertelli M, et al. (2009) International guide to prescribing psychotropic medication for the management of problem behaviours in adults with intellectual disabilities. *World Psychiatry,* **8**(3): 181-186. https://doi.org/10.1002/j.2051-5545.2009.tb00248.x
8. Deb S, Limbu B, Allgar V (2025) Pattern of psychotropic prescribing in adults with intellectual disabilities in the community settings in the UK: a cross-sectional view. *Research in Intellectual and Developmental Disabilities*. https://doi.org/10.1016/j.ridd.2025.104968
9. Deb S, Perera B, Krysta K, et al. (2022a) The European guideline on the assessment and diagnosis of psychiatric disorders in adults with intellectual disabilities. *European Journal of Psychiatry*, **36**: 11-25. https://doi.org/10.1016/j.ejpsy.2021.10.002
10. Deb S, Roy M, Limbu B, et al. (2023) Randomised controlled trials of antipsychotics for people with autism spectrum disorder: a systematic review and a meta-analysis. *Psychological Medicine*, **53**: 7964-7972. https://doi.org/10.1017/S003329172300212X
11. Deb S, Unwin GL, Cooper S-A, Rojahn J. (2022b) Problem behaviours. In 'Textbook of Psychiatry for Intellectual Disability and Autism Spectrum Disorder' (Eds. MO Bertelli, S Deb, K Munir, A Hassiotis, L Salvador-Carulla). *Springer Nature*, Cham, Switzerland. p. 145-86. https://doi.org/10.1007/978-3-319-95720-3_7
12. Gil-Llario MD, Díaz-Rodríguez I, Fernández-García O, Estruch-García V, Bisquert-Bover M, Ballester-Arnal R. (2023) Mental Health of People with Intellectual Disabilities Living in Residential Care before, during, and after Lockdown. *Behavioral Science*, **13**; 695. https://doi.org/10.3390/bs13080695
13. Gore NJ, Sapiets SJ, Denne, LD, et al. (2022) Positive Behavioural Support in the UK: A state of the nation report. *International Journal of Positive Behaviour Support*, **12**(1): 4-39.
14. Henderson A, Mcskimming P, Kinnear D, et al. (2020) Changes over a decade in psychotropic prescribing for people with intellectual disabilities: prospective cohort study. *BMJ Open*, **10**: e036862.
15. Holden B, Gitlesen JP. (2004) Psychotropic medication in adults with mental retardation: prevalence, and prescription practices. *Research in Developmental Disabilities*, **25**: 509-521.
16. Marston L, Nazareth I, Petersen I, Walters K, Osborn DPJ. (2014) Prescribing of antipsychotics in UK primary care: a cohort study. *BMJ Open*, **4**: e006135.
17. Maulik PK, Lakhan R, Kishore MT, Sahu A, Bertelli MO, Sagar R. (2022) Prevalence and aetiopathogenesis of Intellectual Developmental Disorders. In M. O. Bertelli et al. (eds.), Textbook of Psychiatry for Intellectual Disability and Autism Spectrum Disorder (eds. MO Bertelli, S Deb, K Munir, A Hassiotis, L Salvador-Carula). *Springer Nature, Cham, Switzerland*. p.51-70. https://doi.org/10.1007/978-3-319-95720-3_2
18. Mehta H, Glover G. (2019) Psychotropic drugs and people with learning disabilities or autism. *Public Health England, UK*.
19. NHS Digital. (2021) Health and Care of People with Learning Disabilities Experimental Statistics 2020 to 2021. NHS Digital (https://digital.nhs.uk/data-andinformation/publications/statistical/health-and-care-of-people-with-

learningdisabilities/experimental-statistics-2020-to-2021/prescribing) (accessed on 08.03.25)
20. NICE (The National Institute for Health and Care Excellence). (2015) Challenging behaviour and learning disabilities: prevention and interventions for people with learning disabilities whose behaviour challenges. Available online: https://www.nice.org.uk/guidance/ng11 (accessed on 08.03.25).
21. Odalović M, Gorman A, Paul A, McCallion P, Burke É, MacLachlan M, McCarron M, Henman MC, Moran M, O'Connell J, Walsh M, Shankar R, Ryan C, O'Dwyer M. (2024) Psychotropic medicines' prevalence, patterns and effects on cognitive and physical function in older adults with intellectual disability in Ireland: longitudinal cohort study, 2009-2020. *British Journal of Psychiatry Open*, **10**: e39, 1-10. https://doi.org/10.1192/bjo.2023.607
22. Ramerman L, Hoekstra PJ, de Kuijper G. (2018) Health-related quality of life in people with intellectual disability who use long-term antipsychotic drugs for challenging behaviour. *Research in Developmental Disabilities*, **75**: 49-58.
23. Sheehan R, Hassiotis A, Walters K, Osborn D, Strydom A, Horsfall L. (2015) Mental illness, challenging behaviour, and psychotropic drug prescribing in people with intellectual disability: UK population-based cohort study. *British Medical Journal*, **351**: h4326. https://doi.org/10.1136/bmj.h4326.
24. Song M, Rubin BS, Ha JWT, Ware RS, Doan T.N, Harley D. (2023) Use of psychotropic medications in adults with intellectual disability: A systematic review and meta-analysis. *Australia and New Zealand Journal of Psychiatry*, **57**(5): 661-674. https://doi.org/10.1177/00048674221149864
25. Sun JL, Watkins L, Henley W, et al. (2023) Mortality risk in adults with intellectual disabilities and epilepsy: an England and Wales case-control study. *Journal of Neurology*, **270**: 3527-3536. https://doi.org/10.1007/s00415-023-11701-6
26. Wittchen HU, Jacobi F, Rehm J, et al. (2011) The size and burden of mental disorders and other disorders of the brain in Europe 2010. *European Neuropsychopharmacology*, **21**: 655-679.
27. World Health Organization. (2004) ICD-10: International Classification of Diseases: tenth revision, 2nd ed. *World Health Organization*, Geneva, Switzerland.
28. World Health Organization. (2019) International classification of diseases for mortality and morbidity statistics (11th Revision), Geneva, Switzerland. https://icd.who.int/browse11/l-m/en (accessed on 08.03.25).

Figure 1 Incidence of mental illness and challenging behaviour per 10,000 person-years of adults with intellectual disabilities between 2015 and 2022



Figure 2 Incidence of new psychotropic prescriptions between 2015 and 2022 per 10,000 person-years of adults with intellectual disabilities



Figure 3 Incidence of new prescriptions of psychotropic medications for challenging behaviour in adults with intellectual disabilities between 2015 and 2022 per 10,000 person-years



Table 1 Prevalence (2010-2022) and incidence (2015-2022) of mental illness, challenging behaviour and neurodevelopmental disorders

Diagnosis	**Prevalence (N=53,551) 2010 N (%)**	**Prevalence (N=62,636) 2022 N (%)**	**Incidence per 10,000 person-years (N=58,678) 2015**	**Incidence per 10,000 person-years (N=62,636) 2022**	**Level of significance (p-value)**
Any mental illness	8419 (15.7%)	10819 (17.3%)	321	240	<0.001
Severe mental illness	3938 (7.4%)	4835 (7.7%)	120	80	<0.001
Psychoses	3,773 (7%)	4,560 (7.3%)	110	74	<0.001
Bipolar disorder	217 (0.4%)	327 (0.5%)	22	11	<0.001
Depressive disorder	1,363 (3%)	1,754 (3%)	93	67	<0.001
Anxiety disorders	3,956 (7.4%)	5,300 (9%)	239	191	<0.001
Dementia	774 (2%)	1548 (3%)	73	86	0.01
Personality disorder	1,899 (4%)	2659 (4.3%)	102	77	<0.001
Sleep disorder	102 (0.2%)	169 (0.3%)	9	11	0.359
Autism	370 (0.7%)	1854 (3%)	17	26	<0.001
ADHD	244 (0.5%)	937 (2%)	11	18	0.002
Challenging behaviour	15,512 (29%)	19,094 (30.5%)	404	343	<0.001

Table 2 Prevalence (2010-2022) and incidence (2015-2022) of psychotropic prescribing

The overall rate of psychotropic prescription					
Psychotropics	Prevalence (N=53,551) 2010 N (%)	Prevalence (N=62,636) 2022 N (%)	Incidence per 10,000 person-years (N=58,678) 2015	Incidence per 10,000 person-years (N=62,636) 2022	Level of significance (p-value)
Any psychotropic	29,616 (55%)	36,981 (59%)	457	383	<0.001
Antipsychotics	18,808 (35%)	23,001 (37%)	317	257	0.469
Antidepressants	9,397 (17%)	15,847 (25%)	334	278	0.146
Anxiolytics	7,705 (14%)	7,953 (13%)	326	297	0.05
Hypnotics/sedatives	290 (0.5%)	635 (1%)	51	71	<0.001
Mood stabilisers	12,158 (23%)	17,488 (28%)	379	368	<0.001
The rate of psychotropics prescribed for challenging behaviour					
Psychotropics	Prevalence (N=15,512) 2010 N (%)	Prevalence (N= 19,094) 2022 N (%)	Incidence per 10,000 person-years (N=17,015) 2015	Incidence per 10,000 person-years (N=19,094) 2022	Level of significance (p-value)
Any psychotropic	12,689 (82%)	16,601 (87%)	507	403	0.004
Antipsychotics	9,590 (62%)	12,078 (63%)	512	427	0.026
Antidepressants	3,098 (20%)	6,378 (33%)	476	413	0.115
Anxiolytics	2,693 (17%)	2,658 (14%)	353	338	0.02
Hypnotics/sedatives	68 (0.4%)	213 (1%)	45	74	0.01
Mood stabilisers	4,634 (30%)	6,987 (37%)	370	414	<0.001
The rate of mental illnesses and challenging behaviour among those who received different psychotropic medications					
Mental illness			**Challenging behaviour**		
Psychotropics	2010	2022	Psychotropics	2010	2022
Antipsychotics for severe mental illness	3475 (18%)	4440 (19%)	Antipsychotics	9590 (51%)	12078 (52%)
Antidepressants for depressive disorder	996 (11%)	1300 (8%)	Antidepressants	3098 (33%)	6378 (40%)
Anxiolytics for anxiety disorders	1232 (16%)	1481 (19%)	Anxiolytics	2693 (35%)	2658 (33%)
Hypnotics/sedatives for sleep disorders	0	2	Hypnotics/sedatives	68 (23%)	212 (33%)
Mood stabilisers for bipolar disorder	137 (1%)	204 (1%)	Mood stabilisers	4634 (38%)	6987 (40%)

Table 3 Characteristics of the study population and psychotropic medicine prescription

All adults with intellectual disabilities in 2022 (n=62,636) (F70-74)	
Gender	
Male	34 014 (54%)
Female	28 622 (46%)
Age group	
<40 years	29 226 (47%)
40-64 years	24 453 (39%)
≥ 65 years	8 957 (14%)
The severity of intellectual disabilities	
Mild and moderate	49 032 (78%)
Severe and profound	7 998 (13%)
Other and unspecified	5 606 (9%)
Incidence of those who displayed challenging behaviour in 2022 (F70x.1 and/or x.8) (n=2147)	
Gender	
Male	1 137 (53%)
Female	1 010 (47%)
Age group	
<40 years	915 (42.6%)
40-64 years	843 (39.3%)
≥ 65 years	389 (18.1%)
The severity of intellectual disabilities	
Mild and moderate	1 791 (83.4%)
Severe and profound	307 (14.3%)
Other and unspecified	49 (2.3%)
Incidence of any new psychotropic medication prescription in 2022 (n=2,398)	
Gender	
Male	1 320 (55%)
Female	1 078 (45%)
Age group	
<40 years	1 115 (46.5%)
40-64 years	861 (35.9%)
≥ 65	422 (17.6%)
The severity of intellectual disabilities	
Mild and moderate	1 851 (77.2%)
Severe and profound	271 (11.3%)
Other and unspecified	276 (11.5%)

Table 4 Factors influencing the occurrence of incidence of different mental illnesses among adults with intellectual disabilities (F70-F79) (multivariate analysis)

		Psychoses (F20-29)		Bipolar disorder (F30-31)		Depressive disorder (F32-39)		Anxiety disorder (F40-48)		Personality Disorder (F60-69)	
		OR (95% CI)	p	OR (95% CI)	p	OR (95% CI)	p	OR (95% CI)	p	OR (95% CI)	p
Gender	Women	N/A	N/A	1.259 (1.090; 1.454)	0.002	1.507 (1.413; 1.608)	<0.001	1.337 (1.286; 1.390)	<0.001	0.820 (0.772; 0.871)	<0.001
Age	< 40	reference		reference		reference		reference		reference	
	40–64	1.121 (1.015; 1.239)	0.025	N/A	N/A	1.240 (1.114; 1.380)	<0.001	1.689 (1.581; 1.804)	<0.001	2.900 (2.546; 3.303)	<0.001
	≥ 65	1.154 (1.044; 1.276)	0.005	N/A	N/A	1.371 (1.233; 1.523)	<0.001	1.259 (1.177; 1.347)	<0.001	2.050 (1.795; 2.341)	<0.001
The severity of ID	Mild and moderate	reference		reference		reference		reference		reference	
	Severe and profound	2.684 (2.243; 3.212)	<0.001	1.231 (0.913; 1.658)	0.173	1.097 (0.980; 1.229)	0.109	0.904 (0.845; 0.968)	0.004	1.530 (1.331; 1.759)	<0.001
	Other and unspecified	1.172 (0.954; 1.442)	0.131	0.889 (0.620; 1.276)	0.524	0.565 (0.482; 0.661)	<0.001	0.391 (0.354; 0.432)	<0.001	0.417 (0.344; 0.506)	<0.001
Challenging behaviour		2.529 (2.382; 2.686)	<0.001	2.085 (1.796; 2.420)	<0.001	N/A	N/A	1.129 (1.082; 1.179)	<0.001	1.626 (1.530; 1.729)	<0.001

Multivariate analysis of factors influencing the incidence of psychotropic medication and occurrence of incidence of psychiatric disorders among adults with intellectual disabilities with odds ratio and p-values. CI= Confidence Interval, N/A= Not applicable (no significant association was found), OR= Odds ratio, and P= p-values.

Table 5 Factors influencing the incidence of psychotropic medication prescribing among adults with intellectual disabilities (F70-F79) (multivariate analysis)

		Antipsychotics		Antidepressants		Anxiolytics		Hypnotics and sedatives		Any psychotropic	
		OR (95% CI)	p	OR (95% CI)	p	OR (95% CI)	p	OR (95% CI)	p	OR (95% CI)	p
Gender	Women	N/A	N/A	1.143 (1.105; 1.182)	<0.001	1.163 (1.126; 1.202)	<0.001	N/A	N/A	N/A	N/A
Age	< 40	reference		reference		reference		reference		reference	
	40–64	0.729 (0.694; 0.767)	<0.001	0.920 (0.873; 0.970)	0.002	1.092 (1.036; 1.152)	0.001	0.545 (0.485; 0.612)	<0.001	1.035 (0.989; 1.083)	0.138
	≥ 65	0.688 (0.655; 0.724)	<0.001	0.825 (0.783; 0.870)	<0.001	1.098 (1.042; 1.158)	<0.001	0.788 (0.706; 0.880)	<0.001	0.937 (0.895; 0.980)	0.005
The severity of ID	Mild and moderate	reference		reference		reference		reference		reference	
	Severe and profound	N/A	N/A	0.923 (0.868; 0.982)	0.011	0.803 (0.760; 0.849)	<0.001	0.621 (0.552; 0.699)	<0.001	0.853 (0.812; 0.895)	<0.001
	Other and unspecified	N/A	N/A	0.747 (0.690; 0.807)	<0.001	0.712 (0.663; 0.766)	<0.001	0.593 (0.507; 0.693)	<0.001	0.783 (0.735; 0.834)	<0.001
Challenging behaviour		2.198 (2.124; 2.276)	<0.001	1.892 (1.827; 1.960)	<0.001	1.101 (1.062; 1.142)	<0.001	N/A	N/A	1.167 (1.130; 1.205)	<0.001
Psychoses		1.357 (1.285; 1.434)	<0.001	1.184 (1.119; 1.254)	<0.001	1.107 (1.044; 1.173)	0.001	N/A	N/A	0.728 (0.685; 0.774)	<0.001
Bipolar disorder		1.287 (1.087; 1.524)	0.003	N/A	N/A	N/A	N/A	N/A	N/A	0.739 (0.600; 0.911)	0.005
Depressive disorder		1.694 (1.572; 1.825)	<0.001	1.854 (1.729; 1.987)	<0.001	1.522 (1.412; 1.641)	<0.001	1.356 (1.121; 1.640)	0.002	N/A	N/A
Anxiety disorder		2.602 (2.487; 2.722)	<0.001	3.259 (3.126; 3.398)	<0.001	2.216 (2.119; 2.316)	<0.001	2.035 (1.823; 2.272)	<0.001	1.606 (1.538; 1.678)	<0.001

Multivariate analysis of factors influencing the incidence of psychotropic medication and occurrence of incidence of psychiatric disorders among adults with intellectual disabilities with odds ratio and p-values. CI= Confidence Interval, N/A= Not applicable (no significant association was found), OR= Odds ratio, and P= p-values.